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A B S T R A C T
As cancer drug prices rise, it remains unclear whether the cost of new interventions is related to their beneficial
impact for patients at a societal-level. Using data for 2003–2015 from the IQVIA MIDAS® dataset, the re-
lationship between cancer drug costs and drug clinical benefits was studied in four countries with different
approaches to drug pricing. Summary measures of drug clinical effects on overall survival, quality of life, and
safety were obtained from a review of health technology assessments. Mean total drug costs for a full course of
treatment were estimated using standard posology for each medicine and in each country. Regression analysis
was used to test whether, at a societal-level, the cost of recently licensed drugs is related to their beneficial
impact for patients. Across all eligible medicines, average treatment costs were lowest in France and Australia
and highest in the UK and US. Compared with Australia, France, and the UK, cancer medicines were on average
between 1.2 and 1.9 times more expensive in the US, where the average total per patient cost for treatment was
$68,255.17. Costs for new cancer medicines are high and, at best, only weakly associated with drug clinical
benefits. The strength of this relationship nevertheless varied across countries. Some new cancer drug-
s—particularly in the US—may be neither affordable nor clinically beneficial over existing treatments. While all
countries can benefit from strategies that more robustly align price with therapeutic benefit in cancer drugs, the
US stands out in its opportunity to improve both affordability and value in cancer drug treatment.
1. Introduction
Prices have risen faster for cancer drugs than those associated with
most other diseases (Bach, 2009; Savage et al., 2017; Vogler et al.,
2016). These trends have led to concerns that escalating costs may
cause health insurers and payers to restrict access to high-cost treat-
ments (Goldman et al., 2007), and make it difficult for patients to af-
ford, or remain adherent with, life-extending medicines, ultimately
impacting patient care (Bestvina et al., 2014; Experts in Chronic
Myeloid Leukemia, 2013; Weaver et al., 2010).
Notwithstanding important questions about the affordability of new
drugs (World Health Organization, 2018), some have suggested that
high prices for new cancer drugs may be justified if they offer equally
large clinical benefits (Mailankody and Prasad, 2015). The concept of
healthcare value as health outcomes achieved per dollar spent under-
pins many of the conceptual frameworks have been proposed to assess
the value of new cancer drugs in relation to existing treatments
(Chandra et al., 2016; Frakt, 2016; Maervoet et al., 2016; Neumann and
Cohen, 2015; Porter, 2010; Schnipper et al., 2016, 2015). Their goals
and methods nevertheless often differ (Leopold et al., 2018; Neumann
and Cohen, 2015), raising questions on how to reliably compare the
clinical impact and cost of new drugs in medical oncology and whether
the cost of interventions is related to their beneficial impact for patients
at a societal-level (Schnipper et al., 2015).
In the United States and other developed countries, different com-
binations of governmental interventions and market-based strategies
are used to reign in on the cost-benefit relationship in prescription drug
markets. These may manifest as generic competition, price discounts
and freezes, profit controls, reference pricing, and health technology
assessment (HTA) in price setting (Carone et al., 2012; US Department
of Commerce, 2004).
For instance, France has traditionally negotiated drug prices directly
with manufacturers on the basis of HTA, including comparative clinical
efficacy data, after they have been licensed for use. Drugs that are
deemed to provide little to no added clinical benefit over existing
treatments are only publicly listed if they come at a lower price or
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induce cost savings (Haute Autorité de Santé, 2014; Rodwin, 2019).
While the United Kingdom generally permits free drug pricing for li-
censed medicines, a national rate-of-return regulation scheme includes
mechanisms for price cuts and profit controls. Cost-effectiveness ana-
lysis is also used as a key criterion in drug reimbursement, which may
indirectly pressure manufacturers to lower drug prices when cost-ef-
fectiveness is not realized (Schoonveld, 2015). The impact from this
policy may be particularly strong in oncology, as all newly licensed
cancer drugs are now referred to the national HTA agency for re-
commendations on whether they should be made available for routine
commissioning throughout the National Health System (NHS)(NHS
England Cancer Drugs Fund Team, 2016). Historically a model for
governments seeking to contain drug expenditures (Doran and
Alexander Henry, 2008), Australian drug prices have generally been
characterized as low to comparable with those observed elsewhere
(Australian Government Productivity Commission, 2001; Kanavos
et al., 2013; Medbelle, 2019; Vogler et al., 2016). Australian authorities
use internal reference pricing for drugs that are deemed to be clinically
comparable to existing treatments, and recommendations for public
coverage may be based on pharmacoeconomic evaluations and cost-
minimization assessments (Verghese et al., 2019; Vitry et al., 2015).
Single- or multi-source medicines that are deemed to be reimbursable
may also be subject to price negotiations, rebates, mandatory price
reductions, and statutory price disclosure (Paris and Belloni, 2014;
Vitry et al., 2015). Managed Entry Agreements (MEAs) may be used to
optimize cost-effective commissioning of drugs when their clinical
benefits or financial impact are uncertain. When, how, and for what
purpose these contractual agreements are used nevertheless varies
across countries (Pauwels et al., 2017; Robinson et al., 2018; Verghese
et al., 2019). In contrast, drug pricing policies in the United States are
fragmented (Blumenthal and Squires, 2016) and do not generally focus
on enhancing the cost-effective use of medicines. In all settings, the use
and impact of market-regulating strategies may also be influenced by
assessments of health prospects, treatment intent, unmet health needs,
and availability of alternative treatments (Dolan et al., 2005; Simoens,
2011; Tordrup et al., 2014; Wellman-Labadie et al., 2010), with disease
type and rarity potentially influencing cancer drug pricing (Chicoye and
Chhabra, 2009; Drummond et al., 2007; Simoens, 2011; Turkstra et al.,
2015).
The extent to which strategies currently used in different countries
ultimately deliver value to patients remains an important question. In
the United States, some have reported a positive correlation between
the episode treatment price of new medicines—defined as each drug's
monthly cost to the Medicare program—and incremental survival
benefits (Howard et al., 2015). Important issues nevertheless remain
unexplored. First, the lack of international comparisons in these studies
leaves readers unable to judge the strength of correlation estimates in
any single country. Second, treatment duration varies across cancer
medicines, making month-denominated drug costs an imprecise mea-
sure of the total financial impact from treatment and biasing drug cost
and value comparisons. The use of annualized costing estimates in other
settings is equally susceptible to this bias (Mailankody and Prasad,
2015) and reflects the lack of a standard approach for estimating cancer
drug treatment costs from unit prices. Finally, regression-based studies
of this sort should consider measures of efficacy, as well as other clin-
ical outcome measures that matter to patients, including quality of life
and safety (Schnipper et al., 2015).
In addressing these gaps, this study tests the value-based proposition
that the cost of cancer medicines newly approved between 2003 and
2013 does indeed bear a relationship to their beneficial impact to pa-
tients in four countries that take different approaches to the regulation
of drug pricing: Australia, France, the United Kingdom and the United
States (World Health Organization, 2015).
2. Methods
2.1. Sample selection
All New Molecular Entities approved by the Food and Drug
Administration (FDA) or European Medicines Agency (EMA) between
2003 and 2013 with an initial, primary anti-cancer indication were
eligible for inclusion. This time period was chosen to coincide with
previous research on the clinical risks and benefits associated with
cancer medicines (Salas-Vega et al., 2016). Supplemental applications,
new non-active treatments, licensing supplements, labeling revisions,
and new or modified indications were not considered, as the benefits
from new drugs for non-initial indications may be unknown at the time
of launch, and thus may be difficult to incorporate into pricing deci-
sions (Howard et al., 2015). To reconcile across available data sources,
cancer drugs were also excluded if they had been approved to treat
multiple disease conditions (n = 9), or if consumer list pricing data
were not available from the IQVIA Multinational Integrated Analysis
System (MIDAS®) dataset (n = 5).
2.2. Data sources
Average annual pricing data for cancer drugs marketed in Australia,
France, the United Kingdom, and the United States was obtained from
the IQVIA MIDAS® dataset. MIDAS® gathers international drug sales
and pricing data via periodic audits corresponding to all domestic
channels of distribution and has previously been used in comparative
pricing and expenditure studies (Danzon and Furukawa, 2006; Divino
et al., 2016; Kanavos et al., 2013). Our MIDAS® extract provided cancer
medicine list prices—set by manufacturers with or without input from
national regulators—collected at the point-of-sale from both hospital
and retail pharmacy settings for each year between 2003 and 2015.
Cancer drugs were defined by IQVIA as any molecule with an L01 or
L02 Anatomical Therapeutic Chemical (ATC) classification. Adjuvant
therapies and products with other ATC codes were excluded from this
analysis. Due to data licensing restrictions, this study does not publish
any list pricing data from MIDAS®.
Summary measures of the comparative effect on overall survival
(OS), quality of life (QoL), and safety from the cancer drugs included in
our sample were adopted from previous publications (Salas-Vega et al.,
2016). Drug-related effects on OS were coded as a continuous variable,
while QoL and safety effects were coded as overall improvement, re-
duction, mixed evidence, or no difference relative to existing standards
of care. In all cases, summary measures of clinical benefit were based on
a review of English-language HTA agency technology evaluations from
Australia, France, and the United Kingdom that were published be-
tween 2003 and May 2015. This time period was chosen to allow for
potential delays between initial drug licensing and publication of HTA
evaluations (Jaksa et al., 2017). The US is a major producer of HTA
evidence, with for instance the United States Centers for Medicare &
Medicaid Services (CMS) and private insurers commissioning HTA re-
ports on new medical technologies to inform coverage decisions at
national and local levels, the Veterans Health Administration (VHA)
performing pharmaceutical HTA through its Pharmacy Benefits Man-
agement Strategic Healthcare Group, and the Institute for Clinical and
Economic Review (ICER) evaluating the clinical and economic value of
new health technologies. However, there is still no national HTA agency
in the US that provides guidance on coverage, pricing, or reimburse-
ment decisions. Nevertheless, unlike licensing authorities such as the
FDA, HTA agencies may have the authority to require submission of all
applicable clinical data, published and unpublished; their assessments
may include any clinical evidence comparing the clinical performance
of new medicines against that of the therapies that would most likely be
replaced by the new intervention (Haute Autorité de Santé, 2009;
National Institute for Health and Care Excellence, 2016; Panteli et al.,
2016; Pharmaceutical Benefits Advisory Committee, 2014); and they
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systematically assess clinical efficacy, quality of life, and safety when
evaluating new medicines, with the former often defined in terms of
patient survival and length of life (Australian Government Department
of Health, 2016; Haute Autorité de Santé, 2012; NICE, 2013). HTA
agency recommendations on drug coverage, pricing, or reimbursement
were not incorporated into this study.
FDA approved primary indications, date of initial FDA approval,
and date of first FDA-approved new or modified indication (target),
new dosing regimen, or modified patient population through Jan 1,
2016 were obtained from FDA prescription drug labels and associated
medical and statistical reviews. For the EMA, these data were obtained
from European public assessment reports (EPARs), and by reviewing
documents from the EMA's drug assessment history. For Australia, they
were obtained by conducting a search of Australian Register of
Therapeutic Goods (ARTG) registrations, Australian Public Assessment
Reports (AusPARs), Therapeutic Goods Administration (TGA) Product
Information documents, the search engine of the TGA website, the
TGA's Orphan Drugs registry, the Pharmaceutical Benefits Scheme
(PBS) A-Z drug list, and Adis Insight (Springer) drug profiles. Data from
each country was linked to the corresponding drug-indication.
Pre-defined recommendations on treatment dose and duration were
extracted from FDA and EMA prescription drug labels that corre-
sponded to initial drug licensure. In some instances, licensing autho-
rities may recommend that treatment continue until clinical benefits
cease, progressive disease occurs, or unacceptable toxicity develops,
[e.g. (European Medicines Agency, 2010; US Food and Drug
Administration, 2007, 2012, 2013)] and clinical trials may also be
designed for to discontinue treatment or allow for patient cross-over
once symptoms deteriorate, toxicity develops, or progression occurs.
Estimates of the treatment duration required to achieve the reported
clinical benefits observed in approval trials were therefore sought from
FDA reviews and prescription drug labels if end-of-therapy re-
commendations were instead based on symptom assessment.
Latest available anthropometric reference data were obtained for
Australia (2014–2015) by querying the Australian Health Survey;
(Australian Bureau of Statistics, 2015) for France (2006–2007), by
contacting the authors of Castetbon et al., (2009); for the United
Kingdom (2010), by querying the Health Survey for England 2010 (NHS
Digital, 2011); and for the United States (2007–2010), by querying the
Anthropometric Reference Data for Children and Adults: United States,
2007–2010 dataset from the United States Centers for Disease Control
and Prevention (Fryar et al., 2012).
Orphan drug status in the United States and European Union and
Anatomical Therapeutic Chemical (ATC) classifications for approved
indications were obtained from FDA and EMA registries of orphan drug
designations and the World Health Organization Collaborating Centre
for Drug Statistics Methodology ATC/Defined Daily Doses (DDD) index.
Australian orphan drug status was obtained from the TGA's orphan drug
registry. A clinical expert also used approved primary indications to
classify all newly licensed cancer medicines by their therapeutic target,
which included malignant ascites, as well as thyroid, gastrointestinal
(GI), lung, hematological, prostate, skin, renal, and breast malig-
nancies.
3. Analysis
3.1. Cancer drug costs
Standard posology was used to estimate the total per patient cost for
drug acquisition over the expected period of treatment with each in-
cluded medicine in Australia, France, the United Kingdom, and the
United States (DrugAbacus, 2017; Goldstein et al., 2017; Herold and
Hieke, 2003; Iyengar et al., 2016; Osterlund et al., 2016; Ray et al.,
2010). Country-specific anthropometric reference data were used to
adjust for international differences in the weight/body surface area
(BSA) of treatment populations, and were stratified by age and sex to
account for age- (adult/pediatric) and sex-specific drug indications.
MIDAS® euro pricing for all countries included in our analysis was
converted to US dollar equivalents using period average euro-USD ex-
change rates for Q4 2015, the delivery quarter of the QuintilesIMS
dataset, and nominal pricing was converted to constant 2015 terms by
using consumer price inflation indices from the World Bank. Costing
estimates were calculated over the first three years following market
launch, and were censored once new or modified indications, dosing
regimens, or modifications to the approved patient population were
approved for the drugs in our sample. Cost analysis was used to describe
mean estimates of the total, per patient cost borne by payers for drug
treatment.
3.2. Cancer drug costs versus clinical benefits
Simple and multiple linear regression analysis was used to test the
value-based proposition that the cost of cancer drugs is associated with
their beneficial impact to patients. Models were designed in accordance
with the American Society for Clinical Oncology's (ASCO) Value
Framework, which recommends that value be assessed by comparing
the cost of cancer regimens with their clinical efficacy (overall survival,
when possible), and effects on toxicity and quality of life (Schnipper
et al., 2016, 2015), implicitly defining value by the strength of positive
associations between measures of drug clinical benefits and cost. The
relationship between measures of drug clinical benefits and cancer drug
spending may vary by country; interaction effects were therefore con-
sidered. Regression analysis used robust standard errors, square root
transformed drug cost estimates in the first year of their marketing, and
modeled OS as a continuous variable and QoL and safety as categorical
variables. As they independently influence cancer drug pricing (Chicoye
and Chhabra, 2009; Drummond et al., 2007; Simoens, 2011; Turkstra
et al., 2015), and may affect assessments of the relative clinical impact
of new medicines, drug indication and orphan status were adjusted for
in regression analyses. Ethical approval was not required for this study
as human subjects were in no way involved and no patient-level data
was used. For more information on study methods, please refer to the
Online Supplementary.
4. Results
62 cancer molecules were approved by the United States (FDA) and
European Union (EMA) between 2003 and 2013 with a primary in-
dication for oncology. Of those, treatment duration and recommended
dosing information was unavailable for 6 drugs. Another 9 were ap-
proved for multiple primary indications or disease conditions, and
pricing data was not available from IQVIA for 5 drugs. The remaining
42 drugs were included in costing analyses (Table 1). Of those, 36 were
assessed for OS by at least one of the three HTA agencies through May
2015 and were therefore included in subsequent analyses examining
the link between drug costs and clinical benefits.
4.1. Cancer drug costs
For all cancer drugs approved between 2003 and 2013 for which
data was available, drug costs were on average lowest in France and
Australia and highest in the United Kingdom and United States (Fig. 1).
The average per patient cost for treatment in these settings equaled
$35,114.98, $35,499.50, $55,616.63, and $68,255.17 respectively,
meaning that cancer drugs were on average between 1.2 and 1.9 times
more expensive in the United States compared with Australia, France,
and the United Kingdom in the first year of drug marketing. This
finding persisted after limiting the sample to drugs that were available
in all four countries. Per patient drug costs for treatment also remained
lowest in Australia ($38,621.04) and France ($42,888.09) in the third
year of drug marketing and highest in the United Kingdom
($56,959.31) and the United States ($76,888.09).
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The total expected per patient cost of cancer drugs over a typical
duration of treatment varied widely. Among the 25 drugs for which
data was available from all four countries, sorafenib was associated
with the smallest cost difference between the least and most expensive
country (27%) in its first year of marketing. Another 4 were associated
with a cost difference of between 33% (degarelix, lapatinib) and 88%
(pazopanib); 7 of between 102% (dabrafenib) and 138% (sorafenib); 5
of between 158% (pertuzumab) and 197% (crizotinib); and 5 of greater
than or equal to 213% (abiraterone, enzalutamide, trastuzumab em-
tansine, bortezomib, and azacitidine), all of which cost the least in
Australia.
4.2. Cancer drug costs versus clinical benefits
Overall survival benefits were, in general, positively associated with
the total expected per patient drug cost for a typical course of treatment
(Fig. 2). However, the magnitude of that association varied across the
four countries that were considered. Simple linear regression showed
that gains in overall survival significantly predicted total per patient
drug costs for a typical course of treatment in the United Kingdom in
the first year that drugs were marketed (b = 9.86, p = 0.04), with
overall survival benefits alone accounting for 12% of the variability in
drug costs. A positive, albeit weaker, relationship was also observed in
France (b = 7.15, p = 0.07). Correlation coefficients were not sig-
nificantly different from zero in the United States (b = 7.07, p = 0.17)
or Australia (b = −1.69, p = 0.79). Similar results were observed in
Table 1
Cancer drug sample.
Active ingredient Indication1 Comparator(s) Total Expected Drug Cost per Patient for Treatment2
Australia France UK US
Ascites
catumaxomab Ascites (EMA) paracentesis . . $10,001-$30,000 .
Breast
trastuzumab emtansine Breast cancer lapatinib + capecitabine $30,001-$50,000 $50,001-$70,000 $90,001-$110,000 > $110,000
eribulin Breast cancer TPC $10,001-$30,000 $10,001-$30,000 $30,001-$50,000 $50,001-$70,000
ixabepilone Breast cancer n/a . . . $50,001-$70,000
lapatinib Breast cancer capecitabine monotherapy $10,001-$30,000 $10,001-$30,000 $10,001-$30,000 $10,001-$30,000
pertuzumab Breast cancer trastuzumab + docetaxel $50,001-$70,000 $50,001-$70,000 $90,001-$110,000 > $110,000
bevacizumab Colorectal carcinoma IFL/5-FU/LV $30,001-$50,000 $10,001-$30,000 $30,001-$50,000 $50,001-$70,000
cetuximab Colorectal carcinoma BSC $30,001-$50,000 $30,001-$50,000 $30,001-$50,000 $90,001-$110,000
panitumumab Colorectal carcinoma BSC/cetuximab (safety) $10,001-$30,000 $10,001-$30,000 $10,001-$30,000 $30,001-$50,000
regorafenib Colorectal cancer placebo > $110,000 $10,001-$30,000 $10,001-$30,000 $30,001-$50,000
ziv-aflibercept Colorectal cancer placebo . $10,001-$30,000 $10,001-$30,000 $50,001-$70,000
azacitidine MDS conventional care < $10,001 $70,001-$90,000 > $110,000 $90,001-$110,000
bendamustine Lymphocytic leukemia chlorambucil . < $10,001 $10,001-$30,000 $50,001-$70,000
bortezomib Multiple myeloma high-dose dexamethasone < $10,001 $30,001-$50,000 $30,001-$50,000 $30,001-$50,000
carfilzomib Multiple myeloma n/a . . $90,001-$110,000 $90,001-$110,000
clofarabine ALL non-comparative $70,001-$90,000 $90,001-$110,000 > $110,000 > $110,000
decitabine MDS n/a . $30,001-$50,000 $50,001-$70,000 $30,001-$50,000
ibrutinib MCL n/a $90,001-$110,000 $70,001-$90,000 > $110,000 > $110,000
nelarabine ALL/LL non-comparative . $10,001-$30,000 $30,001-$50,000 $30,001-$50,000
obinutuzumab CLL chlorambucil $30,001-$50,000 . $50,001-$70,000 $50,001-$70,000
ofatumumab CLL chlorambucil $50,001-$70,000 $50,001-$70,000 $70,001-$90,000 > $110,000
romidepsin Cutaneous lymphoma n/a . . . > $110,000
ruxolitinib Myelofibrosis BSC $30,001-$50,000 $30,001-$50,000 $70,001-$90,000 $50,001-$70,000
tositumomab NHL n/a . . . < $10,001
vorinostat Cutaneous lymphoma BSC . . . $50,001-$70,000
Lung
afatinib NSCLC erlotinib/gefitinib $30,001-$50,000 $30,001-$50,000 $50,001-$70,000 $90,001-$110,000
crizotinib NSCLC pemetrexed < $10,001 $50,001-$70,000 $70,001-$90,000 $70,001-$90,000
erlotinib NSCLC placebo/BSC $10,001-$30,000 < $10,001 $10,001-$30,000 $10,001-$30,000
gefitinib NSCLC paclitaxel + carboplatin < $10,001 . $10,001-$30,000 < $10,001
Prostate
abiraterone acetate Prostate cancer BSC (prednisolone) $10,001-$30,000 $10,001-$30,000 $30,001-$50,000 $30,001-$50,000
cabazitaxel Prostate cancer mitoxantrone $30,001-$50,000 $50,001-$70,000 $70,001-$90,000 $90,001-$110,000
degarelix Prostate cancer leuproprelin + LHRH agonists < $10,001 < $10,001 < $10,001 < $10,001
enzalutamide Prostate cancer placebo $10,001-$30,000 $30,001-$50,000 $50,001-$70,000 $70,001-$90,000
Renal
axitinib RCC BSC $30,001-$50,000 $30,001-$50,000 $50,001-$70,000 $70,001-$90,000
everolimus RCC BSC . $10,001-$30,000 $10,001-$30,000 $10,001-$30,000
pazopanib Advanced RCC BSC/interferon-alfa $10,001-$30,000 $10,001-$30,000 $30,001-$50,000 $50,001-$70,000
sorafenib RCC BSC $10,001-$30,000 $10,001-$30,000 $10,001-$30,000 $10,001-$30,000
temsirolimus RCC interferon-alfa . < $10,001 $10,001-$30,000 .
Skin
dabrafenib Melanoma dacarbazine/vemurafenib (safety) $30,001-$50,000 $30,001-$50,000 $50,001-$70,000 $30,001-$50,000
ipilimumab Melanoma dacarbazine . . > $110,000 > $110,000
trametinib Melanoma dabrafenib $10,001-$30,000 . $30,001-$50,000 $30,001-$50,000
Thyroid
cabozantinib Medullary thyroid cancer placebo . . > $110,000 .
1 EMA indication used in instances where FDA approval was not available. MDS =myelodysplastic syndromes; ALL = acute lymphoblastic leukemia; CLL = Chronic
lymphocytic leukemia; LL = lymphoblastic lymphoma; MCL = Mantle cell lymphoma; NHL = Non-Hodgkin's lymphoma; NSCLC = non-small cell lung cancer;
RCC = renal cell carcinoma. 2 Drug costs were not estimated if drug pricing information was unavailable for countries within our period of analysis, e.g. if medicines
were not licensed for sale. Medicine costing bins are defined in terms of 2015 USD. Drug sample selection and parameters, as described in Methods section.
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subsequent years of drug marketing: overall survival benefits were
positively associated with drug costs corresponding to the second year
of drug marketing in France (b = 8.85, p = 0.02) and both the second
(b = 10.96, p = 0.03) and third (b = 10.53, p = 0.04) years of drug
marketing in the United Kingdom. Drug costs tended to rise with im-
provements in quality of life in France and the United Kingdom, but did
not increase with improvements in safety in any setting (Fig. 2).
Including drug-related effects on OS, QoL, and safety in multiple
regression analysis increased the predictive power of the regression
model (Table 2), suggesting that these measures of drug clinical benefit
can help explain drug costs more than treatment descriptors alone.
Nevertheless, a majority of the model's explanatory power came from
accounting for drug-related effects on OS and quality of life. Breast, GI,
hematological, prostate, skin, and thyroid indications, for example,
were associated with significantly higher drug costs than the reference
malignant ascites indication. The association between orphan status
and higher drug costs under model (3)—preferred based on the ad-
justed R2 statistic—also approached statistical significance (p = 0.06).
Compared to Australia, interactions between country and OS ben-
efits on cancer drug costs were positive and significant in the United
Kingdom and France under the preferred model (3), and their magni-
tudes varied between countries. Interaction terms between there being
no drug-related QoL effect and both the United Kingdom and France
were also significant and negative under alternative model specifica-
tions (4, 6). These findings suggest that while drug clinical benefits are,
in general, weakly associated with costs for treatment, it is also possible
for that relationship to be mediated by domestic policy.
5. Discussion
In part because of the impact of drug costs on healthcare ex-
penditures, medication adherence, and, ultimately, patient outcomes,
the importance of critically assessing the added value of new cancer
drugs has increasingly become apparent to providers, payers, and pol-
icymakers. To better understand the value from spending on new
cancer treatments, this study took a novel approach to examine cancer
drug treatment costs in Australia, France, the United Kingdom, and the
United States, and the relationship between cancer drug costs and their
clinical benefits.
Just as cancer drug prices vary widely across countries (Savage
et al., 2017), so too do their costs corresponding to a typical duration of
treatment. We find that payers in Australia and France generally bear
lower costs for cancer drugs than those in the United Kingdom or
United States. This remains true through to the third year of drug
marketing and even when only considering the drugs that are available
in all four countries. Cancer drug costs are particularly high in the
United States, where treatment with cancer drugs in their first year of
marketing is on average between 1.2 and 1.9 times more expensive than
in Australia, France, and the United Kingdom.
Notwithstanding important questions over affordability, patient
access, and adherence to treatment, high cancer drug costs may be
justified if new medicines offer equally large clinical benefits to pa-
tients. This study finds some evidence to suggest that the clinical ben-
efits from cancer drugs may be associated with their cost for treatment.
However, the strength of this relationship is weak at best, varies across
countries, and is not significantly different from zero in some settings.
Overall survival benefits were predictive of cancer drug costs in France
and the United Kingdom. In both settings, drug costs also tended to rise
with quality of life benefits. Under no circumstance, however, was the
relationship between overall survival, quality of life, or safety benefits
and drug costs significant in Australia or the US.
Why should we care whether the cost of new cancer medicines is
related to their beneficial impact to patients? Consider how the value,
affordability, innovation, and patient choice objectives intertwine.
Lowering drug prices can improve treatment affordability and broaden
access to medicines, two necessary objectives in healthcare decision-
making. Yet, some have suggested that doing so may stifle innovation
and patient choice (Parker-Lue et al., 2015). Accounting for value in
this process can further refine the drive to make drugs more afforda-
ble—it can help identify drugs whose prices are not justified by their
benefits, and thus whose prices may be most subject to review and
negotiation. In a world of limited resources, such efforts may help to
rationalize drug expenditures, maximize health outcomes at a societal
level, and incentivize drug development that is truly clinically mean-
ingful (Claxton, 2007; Howard et al., 2015; Kyle, 2018).
Do we therefore pay for what we get with cancer drugs? This study
offers evidence to refute the notion that cancer drug costs are ne-
cessarily related to their therapeutic benefits (Schnipper et al., 2015).
This is particularly true for the US, where a subset of new cancer
medicines may be both expensive and no better for patients compared
to existing alternatives. Yet, we also find that countries appear capable
of altering the relationship between drug costs and clinical benefits.
That US cancer drug costs are both high and unrelated to therapeutic
benefits suggests that governmental intervention—as utilized by France
and the United Kingdom—may play an appropriate economic role in
the pricing of cancer medicines.
Governments may for instance use cost and clinical efficacy data
within the context of HTA to inform mechanisms that help to ensure
value for money, including price negotiations, arbitrations, and terms
of drug reimbursement. Such an approach may be particularly useful
when there are questions about the cost and health benefits of new
treatments (Sorenson et al., 2008). In the US, CMS is prohibited from
negotiating prices or taking costs into consideration during the drug
reimbursement decision-making process; that process also often does
Fig. 1. Total expected cost of cancer medicines over a typical duration of treatment in the first year of their marketing (percentage share of all eligible cancer
medicines in each country). Bins are defined in terms of thousand 2015 USD. Authors' analysis of data, as described in Methods section.
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Fig. 2. Cost of cancer medicines approved between 2003 and 2013 versus their impact on overall survival, quality of life, and safety (first year of marketing, mean
measure of cost, 2015 USD). Authors' analysis of data, as described in Methods section.
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not consider the clinical evidence supporting drug use (Bach and
Pearson, 2015; Barnieh et al., 2014). CMS may also be required to cover
all or substantially all medicines that fall within six protected classes,
including anti-neoplastics and immunosuppressants (Bach and Pearson,
2015). As healthcare costs rise, Congress has introduced initiatives to
better control drug spending, including by empowering the federal
government to negotiate drug prices (Morten and Kapczynski, 2019)
and recent efforts by CMS help to promote the use of lower-cost alter-
native therapies (Centers for Medicare and Medicaid Services, 2019).
While the US and other countries should consider such initiatives to
improve the affordability of new treatments, their focus on drug costs
raises questions about how they may specifically impact the relation-
ship with drug clinical benefits and value from spending. Additional
research should consider replicating our analysis to include new cancer
medicines to address this question. In the meantime, innovative policies
meant to rationalize drug costs could also be designed to consider drug
clinical benefits.
As it stands, among the countries considered in this study, France
appears to be particularly adept at ensuring that recently licensed
cancer drugs are both affordable and that their costs reflect their ben-
eficial impact to patients. The US stands at the opposite end of this
spectrum: US payers and patients consistently pay more for recently
licensed cancer drugs than those in other countries, yet do so without it
necessarily leading to any greater health benefit. While all countries
share in the opportunity to improve value-for-money in cancer drug
spending, the US may benefit the most from a re-imagined approach to
drug pricing. As the country seeks to contain drug costs while also
improving patient outcomes, other countries may offer lessons on how
to better ensure affordability and value-for-money in oncology.
5.1. Limitations
Our study has several limitations that should be considered. First,
the drug pricing data used in our analysis reflects the list price rather
than the transaction price; confidential discounts and rebates are not
built in (Vogler et al., 2012). Various approaches have been used to try
Table 2
Regression analysis.
Source: Authors' analysis of data, as described Methods section.
Variable1 Model2
(1) (2) (3) (4) (5) (6)
Dep. Var. sqrt_
TCp
sqrt_
TCp
sqrt_
TCp
sqrt_
TCp
sqrt_
TCp
sqrt_
TCp
orphan −0.14 [19.80] 7.67 [24.87] 44.99 [23.74] 51.19 [26.99] 23.79 [29.75] 77.46* [35.18]
breast 65.56* [25.16] 73.87* [34.71] 105.8* [42.46] 109.6* [43.57] 124.5* [60.22] 149.6* [63.14]
gi 50.96* [24.94] 62.42 [34.15] 97.71* [38.33] 97.50* [41.01] 112.20 [56.40] 139.9* [62.99]
hematological 98.67*** [14.54] 89.76*** [24.97] 95.20** [32.46] 102.2** [35.55] 115.1* [48.04] 115.6* [53.08]
lung 25.81 [26.52] 37.37 [42.84] 64.44 [43.92] 74.27 [47.06] 80.20 [58.25] 111.50 [63.22]
prostate 32.59 [30.20] 73.82 [43.46] 109.9* [49.66] 113.3* [49.94] 123.90 [63.25] 153.5* [66.74]
renal 23.81* [11.61] 8.91 [31.55] 5.01 [34.41] −5.42 [36.19] 36.66 [50.77] 11.78 [53.54]
skin 90.83** [30.11] 252.0*** [34.68] 249.3*** [40.45] 273.8*** [42.12] 280.6*** [60.08] 316.6*** [63.83]
thyroid 192.5*** [19.80] 237.4*** [29.07] 274.0*** [28.32] 276.8*** [28.73] 289.5*** [57.64] 342.1*** [63.33]
OS 3.51 [3.456] −6.66 [6.141] 3.63 [3.044] 4.37 [2.938] −0.54 [7.243]
QoL −13.91 [11.18] −13.54 [9.269] −13.19 [9.939]
safety 37.13** [12.17] 36.36** [11.02] 32.97** [11.76]
FR −30.47 [36.62] 78.45* [36.64] 19.12 [13.09] 0.06 [29.90]
UK 3.89 [38.23] 125.3** [37.10] 60.61** [19.13] 38.68 [26.61]
US 44.26 [39.36] 140.1** [43.20] 33.92 [34.81] 26.12 [45.27]
FR # OS 13.49* [6.319] 7.42 [7.764]
UK # OS 15.61* [6.533] 9.51 [7.828]
US # OS 11.43 [6.999] 3.67 [8.436]
QoL_reduce −52.88 [38.29] −70.72 [54.07]
QoL_NE 57.37 [60.49] 96.59 [72.04]
QoL_reduce # FR −47.44 [39.77] 27.53 [84.19]
QoL_reduce # UK −63.19 [41.10] 21.46 [84.42]
QoL_NE # FR −115.8* [57.72] −142.70 [74.42]
QoL_NE # UK −129.9* [59.56] −154.2* [75.09]
QoL_NE # US −111.00 [65.54] −176.2* [80.97]
safety_ME −12.33 [44.16] −28.15 [51.42]
safety_reduce 60.66 [47.34] −32.10 [66.22]
safety_NE 91.11 [61.35] −25.21 [76.99]
safety_ME # FR 35.80 [54.46] 55.68 [62.13]
safety_ME # UK 38.68 [60.99] 50.36 [66.89]
safety_ME # US 80.17 [68.61] 98.18 [80.26]
safety_reduce # FR −30.37 [51.14] 69.10 [68.27]
safety_reduce # UK −32.43 [54.07] 67.68 [73.65]
safety_reduce # US 31.49 [63.38] 153.40 [90.69]
safety_NE # FR 13.28 [66.62] 126.40 [79.79]
safety_NE # UK 10.24 [73.23] 132.80 [85.44]
safety_NE # US 74.49 [75.52] 207.9* [95.69]
Constant 146.1*** [19.80] 45.33 [57.44] 5.76 [68.63] −90.00 [69.11] 12.92 [63.77] −20.23 [66.79]
Observations 136 94 94 94 94 94
R2 0.149 0.295 0.463 0.482 0.444 0.539
Adj R2 0.088 0.19 0.334 0.33 0.228 0.26
1OS = overall survival; QoL = quality of life; improve = overall improvement; reduce = overall reduction; ME = mixed evidence; NE = no established difference
in outcome measure relative to best alternative treatment. 2Square root transformation of the dependent variable, total cost per patient per full expected course of
treatment (TCp) in the first year of marketing. 3Reference categories: ascites; AU; QoL: improve; safety: improve. 4Standard errors (SE) are provided in brackets. ***:
p ≤ 0.01, **: p ≤ 0.05, *: p ≤ 0.10.
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to address this issue, with one, for instance, using disclosed rebate of-
fers from CMS to assume a constant price reduction on the published
price for purchasers of two specialty medicines for Hepatitis C in
multiple countries (Iyengar et al., 2016). Assuming a fixed discount to
published drug prices in our study would have led to drug cost esti-
mates that were proportionally discounted. There is however little
reason to justify one price discount level over another across multiple
products (Mattingly et al., 2018), or across countries. Moreover, any
fixed price reduction would not have impacted our findings regarding
international cost trends or their relationship with drug clinical bene-
fits. We agree with arguments that net prices should be used instead.
However, without information on confidential discounts and rebates,
net prices would have to be calculated from aggregated sales data,
raising questions over how and to what extent they would accurately
reflect the transactional price incurred by any single payer. Despite the
challenges inherent to their use, list prices are set by manufacturers
with or without the input of national regulators. In theory, they may
reflect transactional prices when rebates and discounts are not applied
(e.g. the uninsured, private patients), meaning that our results provide
accurate, international costing estimates in this scenario. Future studies
should nevertheless repeat our analysis as information on transactional
prices become available. We see progress in this regard, with survey-
based methods encompassing a limited number of cancer centers
starting to offer data on the actual cost of some new cancer medicines
(van Harten et al., 2016), and recent bipartisan policy initiatives that
would require CMS to publish drug discounts and rebates (Spanberger,
2019).
Next, 42 drugs were eligible for inclusion in this study. Although
this sample encompasses all New Molecular Entities that had been ap-
proved by either the FDA or EMA with a single, primary anti-cancer
indication over the 10-year period 2003–2013, and which could be
reconciled with the longest longitudinal dataset that is available from
IQVIA, this remains a relatively small sample. Future studies should
build on this analysis by extending it to other countries, or by re-run-
ning it to include additional cancer drugs that have been approved in
the intervening period.
This study is in part based on a review of HTA agency assessments of
the added clinical benefits associated with cancer medicines. To do so,
these agencies evaluate the primary clinical data to perform technology
appraisals. It is well known that clinical research may be subject to
various forms of bias, which may impact the reliability of technology
appraisals by licensing and regulatory authorities. The summary mea-
sures of drug clinical benefits used in this study were based on a review
of technology appraisals from three HTA agencies. The bodies also may
require submission of all relevant information, published and un-
published, including RCTs necessary to complete their appraisal, and
they base their assessments on systematic reviews and expert evalua-
tions of the evidence. This approach not only helps to mitigate any
impact from bias present in the primary clinical evidence, it is also less
subject to interpretation bias and provides a more representative as-
sessment of the clinical impact from new cancer medicines (Salas-Vega
and Mossialos, 2017).
Finally, this study focuses on drug-related effects on OS, QoL, and
safety. This approach is designed to reflect recommendations from
ASCO's Value Framework, which is specific to cancer; was designed
through a deliberative consensus process; is rules-based; weights clin-
ical measures according to their perceived value to patients; explicitly
synthesizes clinical benefits; and incorporates direct costs from treat-
ment (Schnipper et al., 2016, 2015). This study did not consider sur-
rogate measures of efficacy, including progression-free survival and
response rates. If it is accepted that surrogate efficacy markers represent
unique dimensions to the clinical benefits from treatment, then their
absence would mean that our analysis may be prone to bias. However,
ASCO's Value Framework recommends that these variables only be used
to assess efficacy if data on overall survival is not available. For its part,
the FDA states that while surrogate markers of efficacy may be
predictive of clinical benefits, they are “not themselves a measure of
clinical benefit” (US Food and Drug Administration, 2016). Further-
more, there is evidence to suggest that any difference between OS and
PFS is often negligible (Howard et al., 2015).
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